正在加载视频...

视频加载失败

加载此视频时出现问题。这可能是由于临时网络问题，或视频可能不可用。

Introducing Latent-X2 — AI-generated antibodies with drug-like developability and low immunogenicity in human panels, zero-shot. Technical report: Blog: Apply for access: [email protected]

Simon Kohl

3,071 subscribers

54,814 次观看 • 9 个月前 •via X (Twitter)

健康养生教育科学技术

Anya Rossi• Live Now

Private livecam show

29 条评论

Jeff Dean 的头像

Jeff Dean9 个月前

Congrats! 🎉

Simon Kohl 的头像

Simon Kohl9 个月前

Thank you, Jeff!!!

Simon Kohl 的头像

Simon Kohl9 个月前

Latent-X2 achieves high-affinity binders across modalities: scFv fragments — down to low picomolar VHH nanobodies — nanomolar affinities Macrocyclic peptides — hits on K-Ras, matching trillion-scale screens Testing just 4-24 designs per experiment. And as part of our report, we release lab-confirmed binder sequences for each of them.

Simon Kohl 的头像

Simon Kohl9 个月前

But the real breakthrough isn't binding, it's developability. Our designs match or exceed approved therapeutics in head-to-head comparison. Expression yield, thermostability, polyreactivity — drug-like from the first generation.

Simon Kohl 的头像

Simon Kohl9 个月前

And for the first time: immunogenicity assessment of an AI-generated antibody. Latent-X2 VHH binders cleared ex vivo T-cell activation and cytokine release assays across a ten-donor human panel. A critical milestone for clinical translation.

Simon Kohl 的头像

Simon Kohl9 个月前

To enable reproduction, we're publishing the sequence and structure of a lab-validated antibody design for each target — accessible on the Latent Labs Platform without sign-in. See the lab-validated examples section on:

Simon Kohl 的头像

Simon Kohl9 个月前

Super excited to also welcome Stefan Oschmann, former CEO of Merck KGaA, to our strategic advisory board. Drug discovery has long been bottlenecked not by hits, but by development. With Latent-X2, we're getting closer to designing the right molecule from the start.

Simon Kohl 的头像

Simon Kohl9 个月前

Just five months after Latent-X1. Grateful to the team for pushing the frontier. Latent-X2 is available on the Latent Labs Platform, via API and in partnerships with us. Reach out: [email protected] More to come. 🚀

Simon Kohl 的头像

Simon Kohl9 个月前

Check out the antibody design workflow on our platform. I am proud of how easy to use this frontier technology can feel.

Robin Rombach 的头像

Robin Rombach9 个月前

🔥 congrats, Simon!

Simon Kohl 的头像

Simon Kohl9 个月前

Thank you @robrombach - and ofc amazing to have you contribute!

Rishabh 的头像

Rishabh9 个月前

Congrats to the team!! Looks awesome :D

Simon Kohl 的头像

Simon Kohl9 个月前

Thank you, Rishabh!

Chaitanya K. Joshi 的头像

Chaitanya K. Joshi9 个月前

Congrats team!

Simon Kohl 的头像

Simon Kohl9 个月前

Thank you Chaitanya!

Karsten Kreis 的头像

Karsten Kreis9 个月前

Congrats to you and the team, Simon! 🔥

Simon Kohl 的头像

Simon Kohl9 个月前

Thanks a lot Karsten!

Anthara Fairooz 的头像

Anthara Fairooz9 个月前

Exciting innovation! Looking forward to seeing the impact of Latent-X2.

Rishabh Poddar 的头像

Rishabh Poddar9 个月前

I wish more people did work like this!

Rahul 的头像

Rahul9 个月前

Congratulations @saakohl! Latent-X is a game-changer for computational biology and drug discovery, pushing button for picomolar binders could slash timelines on undruggable targets like never before. AI in Science exploding! 🔥

nabajit (bio/acc) 的头像

nabajit (bio/acc)9 个月前

very cool

MrHonkster 的头像

MrHonkster9 个月前

Saving to read later

Amy - AI Girl 的头像

Amy - AI Girl9 个月前

Exciting advancement in AI-generated antibodies! Great potential for health innovation.

Arda Göreci 的头像

Arda Göreci9 个月前

Congrats Simon!

PurePckg 的头像

PurePckg9 个月前

May I ask who was responsible for the frontend development using Mol*? The glass‑like rendering and the elegant handling of selections in each component are truly impressive.

Ava Grace 的头像

Ava Grace9 个月前

Exciting innovation in AI-generated antibodies!

Tony Kulesa 的头像

Tony Kulesa9 个月前

🔥

Evgenii 的头像

Evgenii9 个月前

Nice affinities. It's a pity that no proofs are presented.

Sam Dare 的头像

Sam Dare9 个月前

@micaelabazo @metanova_labs wen?

相关视频

Today we're launching Latent-Y: the world's first autonomous agent for drug design, lab-validated end to end. Give it a research goal. Latent-Y reasons, designs, iterates, and delivers lab-ready antibodies, autonomously or collaboratively, with the biological reasoning of a PhD protein design expert. Technical report: Blog post: Apply for access:

Today we're launching Latent-Y: the world's first autonomous agent for drug design, lab-validated end to end. Give it a research goal. Latent-Y reasons, designs, iterates, and delivers lab-ready antibodies, autonomously or collaboratively, with the biological reasoning of a PhD protein design expert. Technical report: Blog post: Apply for access:

Simon Kohl

121,575 次观看 • 6 个月前

Introducing Latent-X — our all-atom frontier AI model for protein binder design. State-of-the-art lab performance, widely accessible via the Latent Labs Platform. Free tier: Blog: Technical report:

Introducing Latent-X — our all-atom frontier AI model for protein binder design. State-of-the-art lab performance, widely accessible via the Latent Labs Platform. Free tier: Blog: Technical report:

Simon Kohl

57,495 次观看 • 1 年前

Introducing ManipGen: a sim2real agent for zero-shot manipulation. ManipGen handles complex tasks in the real world like organizing shelves, tidying cluttered tables, and more – all from text input and with on human demonstrations!

Introducing ManipGen: a sim2real agent for zero-shot manipulation. ManipGen handles complex tasks in the real world like organizing shelves, tidying cluttered tables, and more – all from text input and with on human demonstrations!

Deepak Pathak

58,160 次观看 • 1 年前

Today, we expand zero-shot drug design beyond binding to the design of multifunctional medicines, the intracellular proteome, and state-of-the-art atomic precision with our model, JAM-2. In a new report (below), we show: 1. The first drug-grade, fully computationally designed multispecific antibodies against five peptide-MHCs: Routine picomolar T-cell activation/cell-killing EC50s, >100-fold selectivity, and drug-like developability 2. The first fully generatively designed, drug-grade dual-variant KRAS G12 multispecifics: They recruit primary T-cells from human donors to kill G12V and G12C presenting cells at pM to single-digit-nM potency, completely sparing wild-type. 3. Atomic accuracy, from sequence alone: Angstrom-level agreement between Cryo-EM and JAM-2 de novo designs, requiring only target sequences (not structure) as input. 4. Unrivaled speed with an AI-native in-house wet lab: Designed, built, and tested five programs in one parallelized campaign, end-to-end in-house in ~6 weeks. 5. A higher validation bar for AI-generated drug candidates: In a field increasingly rife with hype and uneven standards of proof, we provide the highest quality public wet-lab validation of AI-designed antibodies to date. We share experimental methods in full, and invite folks to adopt and build on these standards. Truly individualized therapies will be the most important contribution of AI in drug design. These advances help accelerate this future.

Today, we expand zero-shot drug design beyond binding to the design of multifunctional medicines, the intracellular proteome, and state-of-the-art atomic precision with our model, JAM-2. In a new report (below), we show: 1. The first drug-grade, fully computationally designed multispecific antibodies against five peptide-MHCs: Routine picomolar T-cell activation/cell-killing EC50s, >100-fold selectivity, and drug-like developability 2. The first fully generatively designed, drug-grade dual-variant KRAS G12 multispecifics: They recruit primary T-cells from human donors to kill G12V and G12C presenting cells at pM to single-digit-nM potency, completely sparing wild-type. 3. Atomic accuracy, from sequence alone: Angstrom-level agreement between Cryo-EM and JAM-2 de novo designs, requiring only target sequences (not structure) as input. 4. Unrivaled speed with an AI-native in-house wet lab: Designed, built, and tested five programs in one parallelized campaign, end-to-end in-house in ~6 weeks. 5. A higher validation bar for AI-generated drug candidates: In a field increasingly rife with hype and uneven standards of proof, we provide the highest quality public wet-lab validation of AI-designed antibodies to date. We share experimental methods in full, and invite folks to adopt and build on these standards. Truly individualized therapies will be the most important contribution of AI in drug design. These advances help accelerate this future.

Nabla Bio

180,591 次观看 • 3 个月前

Introducing: Argent Lens 🔍 A design review tool for agent-generated UI. With Lens your AI-agent can propose several design variants. You pick the one you like, leave comments on any part of the UI, and apply the changes. Now available in experimental.

Introducing: Argent Lens 🔍 A design review tool for agent-generated UI. With Lens your AI-agent can propose several design variants. You pick the one you like, leave comments on any part of the UI, and apply the changes. Now available in experimental.

Software Mansion

30,369 次观看 • 3 个月前

I finally gave in and recorded everything I know about AI marketing. Introducing: ✨ The AI Marketing Masterclass ✨ • 14 lessons • 3 hours • Zero to AI-native marketer You don't have to be technical! Grab it for $149 until midnight tonight.

I finally gave in and recorded everything I know about AI marketing. Introducing: ✨ The AI Marketing Masterclass ✨ • 14 lessons • 3 hours • Zero to AI-native marketer You don't have to be technical! Grab it for $149 until midnight tonight.

Corey Haines

12,264 次观看 • 18 天前

Today we launch Latent-Y, our drug design agent. 250 designs free every day for any approved researcher. We are also releasing the first lab results from researchers with early access: Ion channel inhibitors that work. CAR-T cells that kill tumour cells, now in vivo. Binders the malaria parasite cannot mutate away from. Full results: Apply for access:

Today we launch Latent-Y, our drug design agent. 250 designs free every day for any approved researcher. We are also releasing the first lab results from researchers with early access: Ion channel inhibitors that work. CAR-T cells that kill tumour cells, now in vivo. Binders the malaria parasite cannot mutate away from. Full results: Apply for access:

Simon Kohl

26,654 次观看 • 2 个月前

Introducing OpenDocs. A new program in partnership with _ a r t e f a c t o _ providing production support and access to creative AI to documentarians from diverse communities and regions. Learn more and apply at

Introducing OpenDocs. A new program in partnership with _ a r t e f a c t o _ providing production support and access to creative AI to documentarians from diverse communities and regions. Learn more and apply at

Runway Studios

35,690 次观看 • 2 年前

Introducing the first agent for visual development. The Bubble AI Agent is here (in beta) — your in-editor partner that explains, troubleshoots, and builds with you. Now available on AI-generated apps. Read more:

Introducing the first agent for visual development. The Bubble AI Agent is here (in beta) — your in-editor partner that explains, troubleshoots, and builds with you. Now available on AI-generated apps. Read more:

Bubble

10,638 次观看 • 11 个月前

Super impressive, this AI agent can use the web browser like a human. Just describe what you want it to do, and it will automatically operate Chrome for you to achieve your task. Apply for early access to HyperWrite:

Super impressive, this AI agent can use the web browser like a human. Just describe what you want it to do, and it will automatically operate Chrome for you to achieve your task. Apply for early access to HyperWrite:

Lior Alexander

217,721 次观看 • 3 年前

Introducing Gaslight Garage: a box where I put my phones and feed them AI-generated audio nonsense to make them think I want to buy stuff. Practical AI for the people. 👌 I'll report back if my ads change in the next weeks.

Introducing Gaslight Garage: a box where I put my phones and feed them AI-generated audio nonsense to make them think I want to buy stuff. Practical AI for the people. 👌 I'll report back if my ads change in the next weeks.

Karim Jedda

1,151,640 次观看 • 1 年前

introducing lipsync-1.9-beta, setting a new standard for lipsync quality it’s zero-shot—no training data needed. generate and edit natural speech seamlessly in any live action, animation, and AI-generated video this is the biggest update we’ve ever released, it’s the most natural lipsyncing model in the world 🔥 available now, try it in our app or via API 👇

introducing lipsync-1.9-beta, setting a new standard for lipsync quality it’s zero-shot—no training data needed. generate and edit natural speech seamlessly in any live action, animation, and AI-generated video this is the biggest update we’ve ever released, it’s the most natural lipsyncing model in the world 🔥 available now, try it in our app or via API 👇

sync. labs

129,213 次观看 • 1 年前

Most AI action clips feels like it was made by the same model on repeat. These 7 don’t. Every single one was generated with Seedance 2.0 in LTX. Different tones, different shot design, zero repetition. Grab the prompts below 🧵

Most AI action clips feels like it was made by the same model on repeat. These 7 don’t. Every single one was generated with Seedance 2.0 in LTX. Different tones, different shot design, zero repetition. Grab the prompts below 🧵

TechHalla

33,887 次观看 • 3 个月前

Drop 5/14: Introducing Bulbul V3, our latest text-to-speech model. It raises the bar for how human it sounds, while being super robust. In an independent third-party human listening study, Bulbul V3 delivers the highest listener preference, and low error rates across use-cases and languages. See details in our blog, but first watch the video.

Drop 5/14: Introducing Bulbul V3, our latest text-to-speech model. It raises the bar for how human it sounds, while being super robust. In an independent third-party human listening study, Bulbul V3 delivers the highest listener preference, and low error rates across use-cases and languages. See details in our blog, but first watch the video.

Pratyush Kumar

424,540 次观看 • 8 个月前

🔐 Introducing 1Password Unified Access, a new core capability within 1Password Extended Access Management that brings Zero Trust governance to every login, not just those behind SSO. With Unified Access: ✔️ Discover shared + sensitive accounts outside SSO ✔️ Apply Zero Trust governance to every login ✔️ Instantly rotate or revoke access ✔️ Give employees one place to access every app Now in public preview for eligible customers. 👉 Learn more and sign up: #IdentitySecurity #ZeroTrust #AccessManagement #XAM #UnifiedAccess #1Password

🔐 Introducing 1Password Unified Access, a new core capability within 1Password Extended Access Management that brings Zero Trust governance to every login, not just those behind SSO. With Unified Access: ✔️ Discover shared + sensitive accounts outside SSO ✔️ Apply Zero Trust governance to every login ✔️ Instantly rotate or revoke access ✔️ Give employees one place to access every app Now in public preview for eligible customers. 👉 Learn more and sign up: #IdentitySecurity #ZeroTrust #AccessManagement #XAM #UnifiedAccess #1Password

1Password

13,068 次观看 • 8 个月前

Higgsfield Plugin for DaVinci Resolve is live. Generate footage in your timeline, draw on a clip to edit, and apply AI-generated LUTs to your scene. Remove backgrounds, reframe, upscale to 4K. Rebuild any shot to your camera, lens, and aperture on Cinema Studio.

Higgsfield Plugin for DaVinci Resolve is live. Generate footage in your timeline, draw on a clip to edit, and apply AI-generated LUTs to your scene. Remove backgrounds, reframe, upscale to 4K. Rebuild any shot to your camera, lens, and aperture on Cinema Studio.

Higgsfield AI 🧩

174,220 次观看 • 4 个月前

Introducing 𝐀𝐋𝐎𝐇𝐀 𝐔𝐧𝐥𝐞𝐚𝐬𝐡𝐞𝐝 🌋 - Pushing the boundaries of dexterity with low-cost robots and AI. Google DeepMind Finally got to share some videos after a few months. Robots are fully autonomous filmed in one continuous shot. Enjoy!

Introducing 𝐀𝐋𝐎𝐇𝐀 𝐔𝐧𝐥𝐞𝐚𝐬𝐡𝐞𝐝 🌋 - Pushing the boundaries of dexterity with low-cost robots and AI. Google DeepMind Finally got to share some videos after a few months. Robots are fully autonomous filmed in one continuous shot. Enjoy!

Tony Zhao

354,625 次观看 • 2 年前

🤖 Introducing Taskade's AI Teams with Multi-Agent Collaboration, now in beta! Assemble your team of AI Agents for collaboration, intelligent responses, and dynamic interactions. They plan, execute, and manage tasks—all together! Reply 'AI Teams' for early access! ✨

🤖 Introducing Taskade's AI Teams with Multi-Agent Collaboration, now in beta! Assemble your team of AI Agents for collaboration, intelligent responses, and dynamic interactions. They plan, execute, and manage tasks—all together! Reply 'AI Teams' for early access! ✨

Taskade

29,743 次观看 • 2 年前

This morning we unveiled Utah’s approach to artificial intelligence: Pro-Human AI. Pro-Human AI means systems that keep people in the driver’s seat, strengthen learning and agency, and broaden opportunity for every Utahn. Utah is backing that vision with action: a new academic consortium, major workforce investments, and partnerships that accelerate responsible, human-centered innovation. More here:

This morning we unveiled Utah’s approach to artificial intelligence: Pro-Human AI. Pro-Human AI means systems that keep people in the driver’s seat, strengthen learning and agency, and broaden opportunity for every Utahn. Utah is backing that vision with action: a new academic consortium, major workforce investments, and partnerships that accelerate responsible, human-centered innovation. More here:

Governor Cox

16,877 次观看 • 10 个月前